Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06616766 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06616766 · ClinicalTrials.gov record · last posted 2026-08-17

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

Name: A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 — clinical trial record (NCT06616766)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1/2

SponsorYuhan Corporation

Started2024-10-02

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.

Protocol amendment history 1 change detected by DataLookout

2026-08-18

Enrollment increased: 161 → 201 participants

Trial Details

NCT Number	NCT06616766
Lead Sponsor	Yuhan Corporation
Conditions	NSCLC (Non-small Cell Lung Cancer), Solid Tumor
Enrollment	201 participants
Start Date	2024-10-02
Primary Completion	2028-03-15 (estimated)
Study Completion	2028-07-29 (estimated)
Updated on ClinicalTrials.gov	2026-08-17